Engineered L-asparaginase

About Enzyme by Design

Enzyme by Design is a private, preclinical-stage biotech leveraging rational structure-based enzyme engineering to develop safer oncology drugs. Its lead platform aims to eliminate toxic side activities from existing enzyme therapeutics, starting with a next-generation L-asparaginase for acute lymphoblastic leukemia and other hematological malignancies. The company is led by a scientifically strong founding team with deep expertise in structural biology and is supported by NIH/NCI grants, positioning it to address significant unmet needs in cancer care by improving therapeutic safety profiles.

Therapeutic Areas